ScholarIQanswers from OpenAlex & ORCID
Dejan Juric
ResearcherPublications, citations & collaboration network
Dejan Juric is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Dejan Juric have?
ScholarIQindexed works
Dejan Juric has 731 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Dejan Juric have?
ScholarIQcitation count
Dejan Juric has 21,573 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Dejan Juric?
ScholarIQh-index
Dejan Juric has an h-index of 61 in OpenAlex.
What is the i10-index of Dejan Juric?
ScholarIQi10-index
Dejan Juric has an i10-index of 183 in OpenAlex.
What is the ORCID of Dejan Juric?
ScholarIQorcid
The ORCID for Dejan Juric is on the source record.
What is the OpenAlex record for Dejan Juric?
ScholarIQopenalex
The OpenAlex for Dejan Juric is on the source record.
What are the most-cited papers on Dejan Juric?
ScholarIQmost cited works
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura E. Henderson, Jiaoyuan Elisabeth Sun, Emily E. Van Seventer, Joseph M. Gurski, Sabrina Baltschukat, Barbara Schacher-Engstler, Louise Barys, Christelle Stamm, Pascal Furet, David P. Ryan, James R. Stone, A. John Iafrate, Gad Getz, Diana Graus Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy, Andrew X. Zhu
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
Noritaka Tanaka, Jessica J. Lin, Chendi Li, Meagan B. Ryan, Junbing Zhang, Lesli A. Kiedrowski, Alexa Michel, Mohammed U. Syed, Katerina A. Fella, Mustafa Sakhi, Islam Baiev, Dejan Juric, Justin F. Gainor, Samuel J. Klempner, Jochen K. Lennerz, Giulia Siravegna, Liron Bar‐Peled, Aaron N. Hata, Rebecca S. Heist, Ryan B. Corcoran
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S. Walmsley, Tiffany G. Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T. Jakubik, Laura E. Henderson, Leah J. Damon, Daria Timonina, Ioannis Sanidas, Christopher J. Pinto, Mari Mino–Kenudson, James R. Stone, Nicholas J. Dyson, Leif W. Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H. Benes, Jeffrey A. Engelman, Dejan Juric
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E. Krop, Takahiro Kogawa, Dejan Juric, Anthony W. Tolcher, Erika Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I. Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P. Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger‐Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric‐Bernstam
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, Islam Baiev, Umair Majeed, Sylvia A. Reyes, Christopher S. Chen, Karen Zhang, R. Sharman, Pedro Luiz Serrano Usón, Jochen Maurer, Rachna T. Shroff, Colin C. Pritchard, Meng‐Ju Wu, Daniel V.T. Catenacci, M. M. Javle, Luc Friboulet, Antoine Hollebecque, Nabeel Bardeesy, Andrew X. Zhu, Jochen K. Lennerz, Benjamin Kye Jyn Tan, Mitesh J. Borad, Aparna R. Parikh, Lesli A. Kiedrowski, Robin Kate Kelley, Kabir Mody, Dejan Juric, Love Goyal